We conclude that, as with Crohn’s disease, an algorithm or a specific scoring system for ulcerative colitis is needed for the use of anti-TNF drugs as first-line treatment in pediatric ulcerative colitis. This evidence concerns the gene TNF and ulcerative colitis.